Dr Reddy's net down 26% at Rs 134.6 cr

Total revenues of of the company grew by 25 per cent during the period to Rs 1,503.8 crore, compared with Rs 1,198.3 crore posted in the corresponding previous year quarter.

A press release said revenues from global generics business grew by 25 per cent to Rs 1,030 crore during the quarter, driven mainly by growth in North America, Russia and Germany. Revenue growth of 62 per cent in North America was driven by a combination of volume growth in key existing products, new product launches in the last 12 months and acquisition of Shreveport facility in the US.

Revenues from Germany, where Dr Reddy's acquired Betapharm during the last year, increased by 20 per cent. About 100 products have been transferred to Dr Reddy's own supply chain network, of which 14 products have been transferred to India, said the release.

Business in Russia also grew by 21 per cent, driven by key brands such as Nise, Ketorol and Cetrine. Revenues from pharmaceutical services and bulk drug sales increased by 27 per cent during the quarter, to Rs 460 crore. Domestic business also grew by 9 per cent during the quarter to reach Rs 220 crore.